Data as of Sep 17
| +1.23 / +5.49%|
Prothena Corp. Plc is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion. It focuses on therapeutic monoclonal antibodies directed specifically to disease causing proteins. The company's antibody-based product candidates target a number of potential indications including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002) and novel cell adhesion targets involved in inflammatory diseases and cancers (PRX003). Prothena was founded on September 26, 2012 and is headquartered in Dublin, Ireland.
|Dale B. Schenk||President, Chief Executive Officer & Director|
|Tran B. Nguyen||Chief Financial Officer & Head-Investor Relations|
|Gene G. Kinney||CSO & Head-Research & Development|
|Martin Koller||Chief Medical Officer|
|Karin L. Walker||Chief Accounting Officer & Controller|